Tag: Gene Therapy

Sarepta Therapeutics starts manufacturing partnership with Paragon Bioservices

Sarepta Therapeutics announced that it has entered into a long-term strategic manufacturing partnership with Paragon Bioservices which will provide access to additional manufacturing capacity.

Novartis to invest $91.5 million in cell and gene therapies manufacturing

The pharma giant Novartis has announced plans to invest $91.5 million over three years on a production site for cell and gene therapies. The goal is to enable new treatments to be delivered in Europe.

PTC Therapeutics buys a biotech focused on gene therapy

PTC Therapeutics announced that it has successfully completed the acquisition of Agilis Biotherapeutics, a private biotechnology company.

Takara Bio receives a manufacturing license from Swedish Medical Product Agency

stem cells
Takara Bio announced that the Medical Products Agency granted a manufacturing license for derivation and banking of human embryonic stem (hES) cells to be produced under GMP conditions.

Astellas buys British gene therapy company Quethera

Astellas Pharma and Quethera Limited announced that Astellas has acquired Quethera, a gene therapy company, that is focused on developing novel treatments for ocular disorders, such as glaucoma.

MedImmune and 4D Molecular Therapeutics to collaborate on AAV gene therapy

MedImmune, the global biologics research and development arm of AstraZeneca, and 4D Molecular Therapeutics announced a collaboration to develop and commercialize a gene therapeutic for patients with chronic lung disease.

BioNTech and Genevant Sciences entered into a mRNA therapy collaboration

BioNTech AG and Genevant Sciences announced that they have entered into a collaboration to develop five mRNA therapeutic programs for rare diseases with high unmet medical need.

BrainStorm Cell Therapeutics develops NurOwn: ALS therapy

The first company has provided a potential out-of-pocket price for patients who seek access through the recently passed federal Right-to-Try legislation and it’s not cheap. BrainStorm Cell Therapeutics could charge more than $300,000 for its Phase III experimental amyotrophic lateral sclerosis therapy NurOwn.

Sarepta Therapeutics and Brammer Bio start a manufacturing cooperation

gene therapy
Sarepta Therapeutics, a biopharmaceutical company focused on the discovery and development of genetic medicine to treat rare neuromuscular diseases, entered into a long-term strategic manufacturing partnership with Brammer Bio.

Regenxbio receives $100 million license payment from Novartis

REGENXBIO announced that it has received an accelerated license payment of $100 million under its license agreement with AveXis, due to the acquisition of AveXis by Novartis.

BIOCAD will invest $26 million in infrastructure for gene therapies development

The agreements on collaboration and joint research in the area of adoptive immunotherapy were signed between V.A. Almazov National Medical Research Center and BIOCAD, a biotech company, on May 24, 2018.

Horizon 2020 provides EUR 3.6 million financing to CombiGene

Horizon 2020, the EU framework programme for research and development, will invest 3.6 million euros in CombiGene’s ongoing development and commercialization of the company’s gene therapy project.

Belgian biotech Celyad received the required funding to keep up with CAR-T race

Celyad (formerly known as Cardio3 BioSciences), a clinical-stage biopharmaceutical company focused on the identification and development of specialized cell based therapies, has raised €40.1 million in a global offering.

Vectalys and FlashCell formed a new gene therapy company

Vectalys, a leading biotech company specialized in manufacturing lentiviral solutions, and FlashCell, a company developing non-integrating lentiviral delivered RNA therapeutics, merged to create Flash Therapeutics.

CGT Catapult officially launched its cell and gene therapy manufacturing centre

Cell and Gene Therapy Catapult officially opened its unique cell and gene therapy manufacturing centre. Backed by investment from UK Government, the centre will support and develop the global cell and gene therapy industry.

The Government of India submitted a draft amendment on cell therapies

stem cells
The Ministry of Health and Family Welfare of India, after consultations with the Drugs Technical Advisory Board (DTAB), has proposed a draft amendment that defines stem cell-based products (SCBP).